Analyst Price Target is $26.29
▲ +443.09% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $26.29, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 443.09% upside from the last price of $4.84.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in Altimmune. This Buy consensus rating has held steady for over two years.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.